AVIR — ATEA PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ATEA PHARMACEUTICALS INC (AVIR)
ATEA PHARMACEUTICALS INC (AVIR) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $2M. Across recent filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AVIR
How many top investors track AVIR
A small number of top investors own this.
AVIR Ownership Composition
How ATEA PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Other77.8%
- Hedge Funds22.2%
Tracked investors reporting AVIR
- Izzy EnglanderMar 31, 2026Millennium ManagementShares349.9KValue$1.9M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares119.6KValue$643.2K% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares69.8KValue$375.5K% Portfolio0.00%
Recent activity
- $2.5MFeb 17, 2026
- $1.9MMay 15, 2026
- New$228.1KFeb 17, 2026
- New$375.5KMay 15, 2026
- New$643.2KMay 15, 2026
- New$302.3KNov 14, 2025
Frequently asked questions
- How many institutional investors hold AVIR?
- 3 tracked institutional investors disclosed a position in AVIR (ATEA PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of AVIR?
- Izzy Englander, Millennium Management, holds the largest disclosed position in AVIR, valued at $2M.
- Did institutional ownership of AVIR increase or decrease?
- Across recent 13F filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 fully exited AVIR.
- Where does this AVIR ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.